Arrhythmias and COVID-19: A review

Authors: Parinita Dherange, MBBS¹, Joshua Lang, MD¹, Pierre Qian, MBBS, PhD¹, Blake Oberfeld², William H. Sauer, MD, FHRΣ¹, Bruce Koplan, MD¹, Usha Tedrow MD, MSc, FHRΣ¹

¹Clinical Cardiac Electrophysiology, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
²Harvard Medical School, Boston, MA 02115, USA

Address for correspondence:
Usha Tedrow, MD MSc
Department of Clinical Cardiac Electrophysiology,
Brigham and Women’s Hospital and Harvard Medical School
75 St. Francis Street, Boston, MA 02115
Phone: 857-307-1947, Fax: 857-307-1944
Email: utedrow@bwh.harvard.edu

Acknowledgement:
Graphic design supplemented by BioRender

Original submission declaration:
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, that it is not under consideration for publication elsewhere, that its publication is approved by all authors.

Conflicts of interest information for all author:
The authors report no conflicts of interest for the review content

Funding/support information:
No
Information on the relevant ethical approvals or informed consent procedures:

Not applicable
Abstract:
Current understanding of the impact of COVID-19 on arrhythmias continues to evolve as new data emerges. Cardiac arrhythmias are more common in critically ill COVID-19 patients. The potential mechanisms that could result in arrhythmogenesis among COVID-19 patients includes hypoxia caused by direct viral tissue involvement of lungs, myocarditis, abnormal host immune response, myocardial ischemia, myocardial strain, electrolyte derangements, intravascular volume imbalances and drug sides effects. To manage these arrhythmias, it is imperative to increase the awareness of potential drug-drug interactions, to monitor QTc prolongation while receiving COVID therapy and provide special considerations for patients with inherited arrhythmia syndromes. It is also crucial to minimize exposure to COVID-19 infection by stratifying the need for intervention and using telemedicine. As COVID-19 infection continues to prevail with a potential for future surges, more data is required to better understand pathophysiology and to validate management strategies.

Keywords: COVID-19, SARS-CoV-2, Arrhythmias, QT prolongation, Torsades De Pointes, Channelopathies, Myocarditis

Condensed Abstract:
Current understanding of the impact of COVID-19 on arrhythmias continues to evolve as new data emerges. This review highlights the potential mechanism of arrhythmias, management of arrhythmias as well as provides crucial strategies to minimize exposure to COVID-19 infection. As COVID-19 infection continues to prevail with a potential for future surges, the review provides critical information to minimize the impact of COVID-19 and arrhythmias associated with it.

Abbreviation List
AAD = antiarrhythmic drugs
ARDS = acute respiratory distress syndrome
BrS = brugada syndrome
CPVT = catecholaminergic polymorphic ventricular tachycardia
COVID-19 = coronavirus disease 2019
ICD = implantable cardiac defibrillator
LQTS = long QT syndrome
MERS-CoV = middle eastern respiratory syndrome-related coronavirus
PAMPs = pathogen-associated molecular patterns
PPE = personal protective equipment
SARS-CoV-2 = severe acute respiratory syndrome coronavirus-2
SQTS = short QT syndrome
TdP = torsades de pointes
TEE = transesophageal echocardiogram
TTE = transthoracic echocardiogram

Highlights:

- Cardiac arrhythmias are more common in critically ill COVID-19 patients
- Arrhythmias occur not only as a result of direct viral effect but also due to systemic illness and drug interactions.
- Management strategies to minimize the impact on arrhythmias and exposure to COVID-19 infection are imperative.
- More data is required to better understand the pathophysiology and to validate management strategies.
Arrhythmias And COVID-19: A Review

Introduction

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) which causes coronavirus disease 2019 (COVID-19) was first officially reported in Wuhan, Hubei Province in China on 31 Dec 2019 (1). Spreading rapidly, COVID-19 has now been classified as a pandemic with far-reaching impact on the world’s health and economic sectors. Millions of coronavirus cases have been reported so far (2) and several efforts are underway to better define the epidemiology of the disease (3). While many cases remain asymptomatic, the most common symptoms include cough, fever, and fatigue. A minority of patients experience complications such as acute respiratory distress syndrome (ARDS) and other end organ damage (4). Of particular concern is cardiac injury, defined as elevation of high sensitivity troponin I above the 99th percentile, which appears common. One case series of 146 hospitalized COVID-19 patients in China reported an cardiac injury incidence of 20% and a higher mortality of 51.2% compared to 4.5% in patients with cardiac injury versus without cardiac injury (5). Similarly in another case series, cardiac injury was manifested in 27.8% of 187 COVID-19 patients and presence of cardiac injury was associated with fatal outcomes with a significantly higher mortality of 59.6 % compared to patients without cardiac injury (8.9%) (6). In an observational cohort study of German patients who recently recovered from COVID-19 illness and underwent cardiac magnetic resonance with a median duration of 71 days since COVID-19 diagnosis, were found to have cardiac involvement in 78% of the patients and ongoing inflammation in 60% of the patients irrespective of the severity and overall course of the illness (7). One aspect of cardiac injury and overall critical illness is an increased risk for cardiac arrhythmias. In this review, we present the current state of knowledge in the potential mechanism and manifestations of cardiac arrhythmias in
COVID-19 infected patients to provide a resource for clinicians during this rapidly evolving crisis.

Data on arrhythmia from previous epidemics and the current COVID-19 outbreak

Since we currently have limited data on the current SARS-CoV-2 outbreak, it is worthwhile to understand from previous historic coronavirus epidemics due to SARS-CoV and MERS-CoV. In a case series of 121 patients diagnosed with SARS-CoV syndrome, 71.9% were found to have tachycardia independent of hypotension and fever and 14.9% were found to have bradycardia as a transient event (8). Tachycardia was not further characterized into arrhythmias although one patient was found to have transient atrial fibrillation. It was noted that the tachycardia persisted in 40% of patients at follow up after discharge. In a case series of 70 patients with laboratory confirmed MERS-CoV in 2014 in Saudi Arabia, cardiac arrhythmias including tachyarrhythmias and severe bradyarrhythmia requiring temporary pacemaker occurred in 15.7% of patients (9).

Though influenza belongs to a different family of viruses, it is worthwhile to note its role in arrhythmias as both COVID-19 and influenza are believed to cause myocarditis and arrhythmias (10). Influenza has been noted to cause various tachyarrhythmias, heart block, and ventricular fibrillation, though most have been presumed to be secondary to myocarditis (11). A survey-based study conducted by Madjij et al., patients with implantable cardiac defibrillator (ICD) or cardiac resynchronization therapy defibrillator were noted to have more ICD shocks delivered during influenza season than during other periods of the year. Also, patients with high influenza activity were reported more likely to have a ventricular arrhythmia treated with shock and with anti-tachycardia pacing (12).
Our initial understanding on incidence of arrhythmias in SARS-CoV-2 outbreak was from retrospective studies from Wuhan, China. In a case series of 137 patients of coronavirus in tertiary hospitals in the Hubei province in China, nearly 7.3% reported palpitations as the initial symptoms (13). In another similarly sized study, 16.7% of patients were reported to have arrhythmias, with a higher incidence of 44.4% Vs 6.9% in ICU patients compared to non-ICU patients (14). A low prevalence of arrhythmias is noted among clinically stable COVID-19 patients in a single day snapshot survey-based data (15). A case series by Guo et al reported an occurrence of 5.9% of sustained episodes of ventricular tachycardia/ventricular fibrillation in 187 hospitalized COVID-19 patients (6).

The data on arrhythmia characterization in COVID-19 patients in the US is now emerging. In a retrospective case series involving 393 COVID-19 patients admitted in 2 hospitals in New York City, 28 patients (7.1%) were found to have atrial arrhythmias whereas only 1 patient who was mechanically ventilated (0.3%) had ventricular arrhythmias (16). With the current data, arrhythmias are noted to be more frequent in critically ill patients. Among 115 COVID-19 patients, atrial arrhythmias were noted in 16.5% of the patients which were all admitted to the intensive care unit (17).

There are several manifestations of arrhythmias observed in COVID-19 patients. Bradyarrhythmias have been described by several authors in the literature. A case of transient complete heart block requiring cardiopulmonary resuscitation was reported in a patient with COVID-19 (18). Another case of transient high-grade atrioventricular block was reported which was thought to be as a result of subclinical myocarditis (19). In a case series by He et al, one of the two patients with COVID-19 disease was found to have transient complete heart block along
with temporary occurrence of S1Q3T3 which suggests transient pulmonary artery hypertension secondary to ARDS (20). Along with cases of bradyarrhythmias, tachyarrhythmias including atrial fibrillation, atrial flutter, supraventricular tachycardias as well as ventricular arrhythmias has been reported in patients with COVID-19 disease. A case of multifocal ventricular tachycardia was preceded by ECG findings of ST elevation in a patient with COVID-19 disease (20). A case of acute bilateral pulmonary embolism in a COVID-19 patient later developed sustained monomorphic ventricular tachycardia with syncope requiring cardioversion (21). Also, some of the “repurposed drugs” used for the management of COVID-19 disease have known risk of QTc prolongation which could lead to torsades de pointes (TdP) (22). Brugada-like ECG pattern on presentation was reported in a COVID-19 case who later had a brief episode of supraventricular tachycardia (23). A case of atrial flutter with 2:1 AV block was seen as the presenting rhythm in a male with symptoms of COVID-19 disease who was later tested to be positive for the novel coronavirus (24).

A recent case series published from New York highlights cases of cardiac arrhythmias in COVID-19 infection which includes high grade AV block, new onset atrial fibrillation, polymorphic ventricular tachycardia due to a ventricular premature contraction causing a long-short sequence and a case of cardiac arrest with pulseless electrical activity (25). These manifestations suggest various potential mechanisms for arrhythmogenesis.

Possible mechanism for arrhythmogenesis
Numerous potential mechanisms increase the risk of cardiac arrhythmias during COVID-19 infection. These include various modes of injury to myocardium as well as extracardiac processes that can exacerbate arrhythmias in patients with a preexisting proclivity. In the setting
of a viral infection, chronic cardiovascular diseases can become unstable due to increased metabolic demand and reduced cardiac reserve (26). This imbalance, in association with direct myocardial damage and increased inflammatory response, could increase the risk of acute coronary syndrome, heart failure and cardiac arrhythmias (27,28). Arrhythmias in COVID-19 may result either primarily due to hypoxia caused from direct viral tissue involvement of lungs, myocarditis, abnormal host immune response or secondarily as a result of myocardial ischemia, myocardial strain due to pulmonary hypertension, electrolyte derangements, intravascular volume imbalances and drug side effects. Arrhythmias are not merely due to the direct effect of COVID-19 infection but are likely as a result of systemic illness (29). The potential mechanisms of arrhythmia in COVID-19 are outlined in Figure 1.

The progression of COVID-19 disease has been hypothesized to be across three overlapping yet distinct stages. This includes stage 1 for early infection with constitutional symptoms, stage 2 in which there is viral entry and replication in the type II pneumocytes causing direct viral cytotoxicity and activation of inflammatory immune response leading to ARDS and hypoxia. If the immune response is unable to clear the virus in a productive and protective fashion, stage 3 ensues which is a hyperinflammatory state and there is multiorgan dysfunction due to a cytokine storm (10).

**Hypoxia caused due to direct viral involvement in the lung tissue**

Acute respiratory failure as a result of lung injury from novel coronavirus infection can lead to hypoxia. Following from our understanding of hypoxia induced cellular damage as it is rooted in myocardial ischemia due to coronary occlusion, hypoxia can activate anaerobic glycolysis, reducing intracellular pH and thus increasing cytosolic calcium levels. This, in turn, can facilitate
early and late depolarizations, as well as cause and temporal alterations in the action potential duration (30). Hypoxia also causes an increase in the extracellular potassium levels which decreases the threshold for depolarization, accelerating electrical conduction (30). Additionally, Hypoxemia can also cause reduced electrical coupling and tissue anisotropy due to dephosphorylation of connexin-43 in the gap junctions (31).

Myocarditis

SARS-CoV-2 myocarditis has been reported several times in the literature so far (32,33). The proposed mechanism for the pathophysiology of myocarditis includes direct myocardial injury as a consequence of direct viral tissue involvement (34) or due to extrapulmonary migration of infected alveolar macrophages and can potentially predispose to enhanced arrhythmic risk by disrupting electrical conduction (30). SARS-CoV-2 virus utilizes the spike protein to bind to ACE2 receptors on the myocardial cell membrane (35). In theory, when the SARS-CoV-2 virus attaches to the ACE2 receptors found on the myocardium, there is down-regulation of the ACE2 receptors which causes unopposed angiotensin II accumulation leading to adverse myocardial remodeling by its action on Angiotensin II type 1 receptors (36). Intracellular presence of the virus also inhibits stress granule formation via its accessory protein promoting its replication and causing cell damage. Based on prior in-vitro studies on SARS-CoV virus, amiodarone and other cationic amphiphilic drugs like dronedarone, verapamil and the calcium channel blocker bepridil seem to target this part of the viral life-cycle by accumulating in the late endosomes/lysosomes and increasing the pH of these organelles, thereby affecting coronavirus replication (37).
Another possible mechanism is via cell-mediated cytotoxicity in which primed CD8+ T-lymphocytes migrate to the cardiomyocytes and cause myocardial inflammation. Via cytokine storm, pro-inflammatory cytokines which are released into the circulation augments T-lymphocyte activation which further releases more cytokines resulting in a positive-feedback loop of immune activation and myocardial injury (32). Myocarditis can cause arrhythmia in the acute stage due to direct cytopathic effect causing electrical imbalance, ischemia from microvascular dysfunction, gap junction dysfunction from impaired myocardial expression of connexins or due to ion channel impairment especially seen in patients with overlapping inflammatory channelopathies. In viral myocarditis, host and viral factors can cause structural as well as electrophysiological remodeling which can cause abnormal calcium handling and down regulation of potassium channels leading to prolonged repolarization and abnormal conduction. Prolonged repolarization can induce triggered activity whereas in combination with abnormal conduction (which involves reduced conduction velocity, decreased refractoriness and increased diffusion of conduction in the myocardium) can cause either circus-type reentry or phase 2 reentry without an obstacle (38). Arrhythmia can also be seen in the post inflammatory stage in which variable degrees of myocardial scar can be present promoting reentrant arrhythmias (33).

Tavazzi et al describes a case of COVID-19 presenting with cardiogenic shock and new onset cardiomyopathy with echocardiogram showing dilated left ventricle (LV), severe and diffuse LV hypokinesia (LV ejection fraction 34%) and coronary angiogram showing normal coronaries. Endomyocardial biopsy demonstrated cytopathic interstitial inflammatory cells but no viral particles were observed in the myocyte. This observation suggests myocardial localization was
either due to a viremia phase or due to migration of infected alveolar macrophages in extrapulmonary tissues (39).

*Abnormal host immune response*

Along with a direct role in myocardial injury (40), cytokines including IL-6, TNF-α, IL-1 can modulate the expression and function of potassium and calcium channels (inflammatory cardiac channelopathies) and cause prolongation of ventricular action potential (41,42). Inflammatory cytokines are a well-studied trigger for arrhythmia, especially in Long QT syndrome patients due to overactivation of the cardiac sympathetic system using the hypothalamus-mediated inflammatory reflex and peripheral-mediated activation of stellate ganglion pathway (43) which can lead to QT prolongation (44). Furthermore, IL-6 inhibits CYP450 which increases the bioavailability of QT prolonging drugs (45).

*Myocardial Ischemia*

Potential causes for myocardial ischemia are microvascular dysfunction and hyperinflammatory state leading to activation of inflammatory cells within a pre-existing atherosclerotic plaque causing vasoconstriction due to dysregulation of the coronary vascular endothelial function. In one study, microvascular dysfunction was found to be in the form of disseminated intravascular coagulation (DIC) due to hyper inflammation and immune activation (46). IL-6 and TNF-α can cause both depletion of coagulation and fibrinolytic system leading to bleeding as well as thrombosis (47). The other postulated mechanism of microvascular dysfunction causing myocardial ischemia is via infection-mediated vasculitis. SARS-CoV-2 virus attach to the ACE receptors which are also expressed in arterial and venous endothelial cells (48). Vasculitis can
thus be triggered either as a result of hypersensitivity reaction induced due to direct viral entry in the myocardial endothelial cells or due to indirect immunological response (49). Myocardial injury with ST segment elevation has also been reported in patients with COVID-19 infection (50). Cytokine surge and the inflammatory mediators can also cause acute coronary syndrome due to activation of inflammatory cells within a pre-existing atherosclerotic plaque as well as vasoconstriction due to dysregulation of the coronary vascular endothelial function (51).

Pathogen-associated molecular patterns (PAMPs) are formed with viral products in the systemic circulation which can cause activation of innate immune response as well as activation of inflammasome resulting in the formation of biologically active cytokines (52).

**Myocardial strain**

Right myocardial strain can be seen as a result of pulmonary embolism which has been reported as the most common thrombotic complication in COVID-19 patients (53) or due to pulmonary hypertension causing increased right sided pressures secondary to severe ARDS, sepsis or heart failure (54). Increased right atrial pressure along with increased sympathetic tone in patients with pulmonary hypertension and hypoxia can predispose to increased risk of atrial tachyarrhythmias (55). On the other hand, a case of temporary occurrence of S1Q3T3 which has been previously described in this review was found to have transient complete heart block suggested to be due to transient pulmonary artery hypertension (20).

**Electrolyte derangements**

Arrhythmias due to electrolyte abnormalities as well as its effect on pre-existing arrhythmias has been well studied (56). In a case series, electrolyte disturbances were reported in 7.2% of 416
hospitalized patients with COVID-19 infection (5). These were attributed to COVID-19 associated diarrhea or from renal injury, among other cases. In a retrospective analysis by Diao et al, acute kidney injury was reported in 27% of 85 patients hospitalized with COVID-19 infection (57). A case report of a COVID-19 patient presenting with atrial arrhythmias previously described in this review, was noted to have severe electrolyte disturbances including hypokalemia, hypomagnesemia and hypophosphatemia (24).

Intravascular volume imbalances

Fluid disturbances are commonly encountered in critically ill patients. Intravascular volume imbalances in COVID-19 disease could either be ascribed to sepsis caused from ARDS or due to heart failure. The most commonly encountered arrhythmia in the critical care setting which can be caused due to the above described mechanism among others, is atrial fibrillation (58).

Drug side effects

Many of the “off-label” COVID-19 therapies including hydroxy(chloroquine), lopinavir/ritonavir and azithromycin have either known or possible risk of torsades de pointes (TdP) due to their effect on QT prolongation (59). Hydroxy(chloroquine) and azithromycin inhibit hERG-K+ channel which causes prolongation of action potential, and this along with unopposed inward Na+ and Ca2+ currents trigger early after depolarization that can lead to TdP. In a cohort study of 90 hospitalized COVID-19 patients, the administration of hydroxychloroquine with or without azithromycin was associated with an increased risk of QTc prolongation and risk of TdP (60). Antimalarial drugs hydroxy(chloroquine) not only can cause this fatal side effect of QT prolongation but can also cause advanced atrioventricular conduction block (28). Currently, there
is not enough data on adverse cardiac effects with some other COVID-19 therapies including ribavirin, remdesivir, tocilizumab.

Management of arrhythmias with COVID-19
The goal of managing arrhythmias in patients with COVID-19 is to treat safely by minimizing exposure and by being mindful of drug-drug interactions. There are not enough clinical studies to guide management of arrhythmia in confirmed COVID-19 cases. Treatment of any bradyarrhythmias or tachyarrhythmias in a COVID-19 patient should be similar to treatment as in any patient with arrhythmia due to infection or transient metabolic disturbances. Special consideration should be given to management of arrhythmias in patients with inherited arrhythmia syndrome and management of QTc prolongation while receiving COVID therapy.

Management of arrhythmias in suspected or confirmed COVID-19 cases
European Society of Cardiology (61) as well as Latin American Heart Rhythm Society in collaboration with Colombian, Argentinian, Brazilian and Mexican society of Cardiac Electrophysiology (62) have provided a consensus document for management of various arrhythmias in a confirmed COVID-19 patient focusing on the transient nature of arrhythmias, drug-drug interactions and limiting exposure and personal protective equipment use. The recommendations are summarized below:

Bradyarrhythmias:
Bradycardia including sinus or AV block in COVID-19 patients, can be seen due to drug side effects with use of hydroxy(chloroquine), lopinavir/rotinavir and azithromycin. AV blocks could
also be seen in myocarditis if there is involvement of the conduction system. Intubated patients can experience transient bradycardia during tracheal secretion suctioning or during proning of the patient due to transient increased vagal tone. In patients with persistent bradycardia, use of isoprenaline and atropine can be considered prior to temporary pacemaker implantation (61). Temporary pacemaker implantation is considered a reasonable option prior to implanting a permanent device due to the transient nature of bradyarrhythmias, nature of critical illness, risk of bacterial superinfection and risk of device infection. However, evaluation of a permanent pacemaker should be reassessed after recovery from COVID-19 infection (62).

**Atrial tachyarrhythmias (Supraventricular tachycardia and Atrial fibrillation/flutter):**

Identify and treat secondary causes of atrial tachyarrhythmias like hypoxia, metabolic and electrolyte imbalances, proarrhythmic effect of drugs, or myocardial ischemia.

In patients with supraventricular tachycardia, intravenous adenosine can be used for acute termination although further validation is needed. Electrical cardioversion can be considered in patients with refractory cases and should be postponed in stable and asymptomatic patients. One should have a low threshold to initiate maintenance therapy with beta blockers (BBs) or calcium channel blockers (CCBs) if BBs are contraindicated; however, BB and CCB drug interactions with antiviral drugs should be evaluated prior to starting these medications to avoid bradycardia and QT prolongation (61,62).

In patients with recurrent atrial fibrillation (AF) and Atrial Flutter (AFl) who are hemodynamically stable, consider discontinuing antiarrhythmic drugs (AAD) especially sotalol, flecainide and likely amiodarone and propafenone given serious drug-drug interactions with antiviral drugs and to start rate controlling medications with BBs or CCBs unless
contraindicated, with or without digoxin. Similarly, patients with new onset of AF/AFl with a stable rhythm can be treated with rate control. Rhythm control strategy should be reserved for patients with hemodynamically unstable patients or in congestive heart failure patients (61,62). There is a high risk of immediate recurrence of arrhythmia without the use of any AAD as maintenance therapy, which can be minimized by treating secondary causes of arrhythmias prior to attempting rhythm control strategy.

Rhythm control strategy can be achieved with synchronized cardioversion or AAD medications like amiodarone however close monitoring with caution is recommended with the use of amiodarone in patients undergoing treatment with fingolimod. Propafenone or flecainide is preferred in structurally normal hearts who are on fingolimod (63). Transthoracic echocardiogram (TTE) is recommended only in hemodynamically unstable patients. Thus, it is imperative to note that the CHA$_2$DS$_2$-VASc score may underestimate risk of stroke. Myocardial injury should be considered if new onset left ventricular dysfunction is noted on TTE which would necessitate escalation of immunosuppressants in patients with myocarditis (61,62).

Cardiac Computed tomography can be considered to rule out left atrial appendage thrombus prior to cardioversion if indicated, instead of TEE to avoid aerosol generating procedures (25). In terms of anticoagulation, the consensus is to start early to obviate the need for transesophageal echocardiogram (TEE) if rhythm control is needed. Data suggests that COVID-19 infection can be associated with a hypercoagulable state that might increase the risk for thromboembolism especially in patients with markedly elevated D-dimer levels and severely ill patients admitted in the ICU (64,65). One should reassess rate versus rate control strategy and the need for anticoagulation after recovering from COVID-19 infection.
Ventricular arrhythmias:
Identify and treat secondary causes like hypoxia, metabolic or electrolyte imbalances and proarrhythmic effects of drugs. In patients with ventricular tachycardia (VT) storm not related to the above causes, the first choice of therapy is amiodarone or intravenous lidocaine especially if underlying myocardial infarction is suspected, in addition to sympathetic blockade with esmolol, sedation and possible intubation. In patients with Polymorphic VT/Ventricular fibrillation with prolonged QTc, replace electrolytes to target potassium level >4.5, start intravenous infusion of magnesium and isoprenaline infusion, stop QT prolonging antiviral meds. Temporary pacemaker implantation using flotation guided technique at bedside in emergency situations can be considered to overdrive terminate VT and incase of recurrent TdP or bradycardia (61). One should also assess the need for escalation of therapies including the use of extracorporeal membrane oxygenation (62). Consider TTE in patients with new onset malignant ventricular arrhythmia if not related to QT prolongation. After recovery from COVID-19, evaluate the need for secondary prevention ICD and catheter ablation. If transient cardiomyopathy due to myocarditis is suspected, consider wearable defibrillator devices (61).

Channelopathies and inherited arrhythmia syndrome:
In patients with Long QT syndrome (LQTS), monitor QT interval and cardiac rhythm due to high risk of QT prolongation seen in COVID-19 disease. Hypokalemia should be avoided in patients with COVID-19 associated diarrhea. It is recommended to maintain a potassium level at the higher range of normal. The effect of fever is not much evident with LQTS (except with specific LQTS2 mutation). Whereas in patients with brugada syndrome (BrS), fever can unmask the ECG manifestation of type 1 BrS and thus it is recommended that all patients with COVID-
19 should self-medicate with paracetamol or acetaminophen if they develop fever. High risk BrS patients who develop fever (>38.5°C) despite treatment, should be evaluated in the emergency room and kept under observation if ECG shows type 1 pattern otherwise can be discharged home to limit exposure to SARS-CoV-2 virus in the hospital. Patients with Catecholaminergic polymorphic ventricular tachycardia (CPVT) have adrenergic related ventricular arrhythmias and thus of catecholamine infusions should be administered with great caution in critically ill patients. BBs and Flecainide should be continued while monitoring interactions with antiviral drugs. Patients with Short QT syndrome (SQTS) do not seem to be at particular risk with COVID-19 (66).

**QT liability with COVID-19 therapy:**

Experimental drugs used for treatment of COVID-19 hold a significant risk for QTc prolongation. A case series by Ramireddy et al reported an increase in QTc in 12% of patients receiving hydroxychloroquine, azithromycin or both; however, no TdP was seen (67). In a randomized controlled trial (CloroCOVID-19 trial) studying the effect of low dose (450 mg twice daily for one day, then 450 mg daily for four days) versus high dose (600 mg twice daily for 10 days) chloroquine in addition to azithromycin in severe COVID-19 patients showed lethality in the higher dose group with an odds ratio of 3.6 (95% CI, 1.2-10.6) and thus recommended against the use of high dose of chloroquine in severe cases (68). Traditionally Tisdale risk score which has been used to calculate the risk for QTc prolongation in hospitalized patients, could also be used to risk stratify COVID-19 patients with a goal to aggressively monitor increased risk patients (69). It consists of age ≥ 68 yrs, female sex, use of loop diuretics, potassium level ≤ 3.5 mEq/L, baseline QTc ≥ 450 ms, acute MI, number of QT prolonging
medications, sepsis, and heart failure. A score of $\leq 6$ predicts low risk, 7-10 medium risk, and $\geq 11$ high risk of drug-associated QT prolongation (70).

An algorithm (59) proposed by Mayo Clinic for patients in whom QTc prolonging drugs like hydroxy(chloroquine) +/- azithromycin, and/or lopinavir/ritonavir are under consideration recommend to obtain a pre-treatment baseline QTc measurement, baseline electrolytes (K+, Ca+2 and Mg+2), to determine if any home QTc prolonging medication can be discontinued and to document high risk CV and co-morbid conditions. QTc can be measured using standard 12 lead ECG, telemetry or mobile ECG devices. However if using a handheld ECG device, either a multi-lead handheld ECG device or a single-lead handheld ECG device in at least three lead positions are recommended as a single position may lead to under-reporting of the QTc interval (71). A QTc measurement of $<460$ ms in pre-pubertal patients, $<470$ ms in post-pubertal males and $<480$ ms in post pubertal females is considered low risk to prescribe or continue therapy. In patients with QTc>500 ms at baseline or an increase in QTc measurement of $\geq 500$ milliseconds or if the change in QT interval is $\geq 60$ milliseconds, 2-3 hours after a dose of hydroxychloroquine or other QT-prolonging agent, recommend re-evaluation of the risk of TdP, discontinue other QTc prolonging medications, correction of all electrolyte abnormalities, placing the patient on continuous telemetry, with consideration of a wearable defibrillator or placement of external defibrillator patches. In patients with a wide QRS either due to bundle branch block or ventricular pacing, wide QRS adjusted QTc can be calculated to account for the wide QRS [wide QRS adjusted QTc = QTc – (QRS – 100 ms)] (59).

A case report by Mitra et al reports a possible benefit of addition of lidocaine or mexiletine to allow combination therapy with azithromycin and chloroquine in patients with a prolonged QT
interval (72). Class 1B antiarrhythmic agents, due to its effect on the late sodium current by blocking the INa-L channel, have been shown to slightly shorten the QT interval and suppress TdP in acquired LQTS. Other known therapies to alleviate risk of TdP, such as maintaining potassium and magnesium levels and heart rates > 70 beats per minute have also been described (72).

Cardiac Drug interaction with COVID-19 therapy

Another important consideration during management of COVID-19 patients is drug-drug interaction in the treatment of COVID-19, especially with concomitant use of antiarrhythmics and anticoagulants. For instance, the levels of hepatically eliminated antiarrhythmic drugs including amiodarone, propafenone, flecainide, quinidine and some novel oral anticoagulants including apixaban, rivaroxaban which are metabolized mainly by different cytochrome P450 (CYP) isoenzymes (e.g. CYP3A4, CYP2C9), can be increased by co-administration of Lopinavir/ritonavir as it inhibits CYP3A4 (66,73). Table 1 summarizes the potential interactions of drugs used for COVID-19 therapy with cardiac drugs.

Optimization of resources and minimizing exposure

In the COVID-19 pandemic, the US healthcare system may face another huge challenge due to shortage of personal protective equipment (PPE), which are routinely used by health care providers to protect themselves from infectious conditions and toxic substances. The fundamental goal is to avoid elective procedures in order to conserve precious resources like PPE and hospital beds and also minimize unnecessary exposure to COVID-19. A practical guide from a New York City Hospital Network describes an approach used to overcome these challenges.
due to the surge of COVID-19 activity in New York by ramping down and restructuring of the electrophysiology services (74).

The nature of procedures in the field of Electrophysiology are mainly non-emergent except for some cardiac arrhythmias which require urgent interventions. The Heart Rhythm Society (HRS) COVID-19 task force(75) has put together a consensus document which divides electrophysiological procedures into urgent/emergent, semi-urgent and non-urgent/elective procedures. Procedures are considered emergent if they would reduce the risk of clinical deterioration, hospitalization or death. Patients requiring EP procedures should be screened for fever and COVID-19 symptoms and should undergo COVID-19 testing. In locations with limited testing availability or with concern for community spread, it may be prudent to consider at least droplet precautions for all EP procedures. N95 masks should be used by all operating physicians and a surgical mask for all patients (74). If needing intubation which is an aerosol generating procedure, it is recommended to consider performing in a negative pressure room either in the EP lab or inpatient ICU before bringing the patient to EP lab. Anesthesia data recommends to limit personnel in the procedure room during intubation or extubation and to follow institutional protocols for the length of time before other personnel can return to the room after intubation which could be between 15-30 minutes based on frequency of air exchanges and the type of PPE used (76). Conscious sedation can be considered by EP attending with backup anesthesia services without compromising patient safety (74). Electrocautery is another aerosol generating procedure which is routinely used during device implantation procedures and the smoke produced can have a significant amount of viral load. Surgical data recommend using low power electrocautery settings and using adequate PPE including goggles or face shield for eye protection as it is considered possible that SARS-COV-2 virus can be transmitted to the
conjunctiva by aerosol although there is no evidence (77). Plasmablade is a soft tissue dissection device other than electrocautery which is routinely used especially during generator changes to limit lead damage, produces less smoke and in theory could be used as a substitute for electrocautery however there is no evidence to support this. Apart from considerations for EP procedures, the HRS COVID-19 task force document (75) also provides guidance regarding management of patients in the outpatient setting via telemedicine as well as regarding minimizing in-person CIED interrogation via remote device monitoring.

Conclusion

Our understanding of the impact of COVID-19 on arrhythmias continues to evolve as new data emerges. Current data suggests that arrhythmias are more frequent in the critical care settings. The increasing risk of arrhythmias in COVID-19 patients is likely as a result of systemic illness and not merely as a result of direct effect of the viral infection. To manage arrhythmias in patients with COVID-19, it is imperative to increase the awareness of potential drug-drug interactions, to monitor QTc prolongation while receiving COVID therapy and provide special considerations for patients with inherited arrhythmia syndromes. It is also crucial to minimize exposure to COVID-19 infection by stratifying the need for intervention and using telemedicine. As COVID-19 infection continues to prevail with a potential for future surges, more data is required to better understand pathophysiology and to validate management strategies.
References


27. Babapoor-Farrokhiran S., Gill D., Walker J., Rasekhi RT., Bozorgnia B., Amanullah A.


45. Lazzerini PE., Acampa M., Capecchi PL., et al. Antiarrhythmic potential of anticytokine


76. Wald SH., Arthofer R., Semple AK., Bhorik A., Lu AC. Determination of Length of Time
for “Post-Aerosol Pause” for Patients Under Investigation or Positive for COVID-19.

Figure Legends

Figure 1: Potential mechanisms of arrhythmia and COVID-19

SARS-CoV-2 virus enters host cells leading to viral infection and immune system activation, affecting the lungs, heart, and other organ systems. Risk of arrhythmias may be broadly mediated by hypoxia, myocarditis, myocardial strain, myocardial ischemia, medication effects, intravascular volume imbalance and electrolyte imbalance.

Abbreviations: ARDS: Acute Respiratory Distress Syndrome; DIC: Disseminated Intravascular Coagulation, IL-6: Interleukin-6, CYP450: Cytochrome P450, SARS-CoV-2: Severe Acute Respiratory Syndrome coronavirus 2

Table Legends

Table 1: Possible drug-drug interaction of drugs used for COVID-19 therapy with cardiac drugs

Abbreviations: ↑/↓: Mild increase/decrease, ↑↑/↓↓: Moderate increase/decrease, ↑↑↑/↓↓↓: Severe increase/decrease, AAD: Antiarrhythmic drugs, BB: Beta Blockers, CCB: Calcium Channel Blockers, HR: Heart Rate, TdP: Torsades de Pointes
Table 1: Possible drug-drug interaction of drugs used for COVID-19 therapy with cardiac drugs

<table>
<thead>
<tr>
<th>TREATMENT</th>
<th>SELECT DRUG-DRUG INTERACTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(Severe: drugs should not be administered, Moderate: potential interaction, need dose adjustments/close monitoring, Mild: weak intensity interaction, need for dose adjustments/close monitoring is unlikely to be required)</td>
</tr>
<tr>
<td>Azithromycin</td>
<td>- ↓ in HR, ↑ PR interval, ↑↑ in QTc interval with very low risk of TdP.</td>
</tr>
<tr>
<td></td>
<td>- AAD drug interactions:</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>(Hydroxy)</td>
<td>- ↓ in HR, ↑ PR interval, ↑↑ in QTc interval with very low risk of TdP.</td>
</tr>
<tr>
<td>chloroquine</td>
<td>- AAD drug interactions:</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Lopinavir/</td>
<td>- ↑ PR interval, ↑↑ in QTc interval with low risk of TdP.</td>
</tr>
<tr>
<td>Ritonavir</td>
<td>- AAD drug interactions:</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Remdesivir</td>
<td>- Unknown</td>
</tr>
<tr>
<td>Ribavirin</td>
<td>- Unknown</td>
</tr>
<tr>
<td>Fingolimod/</td>
<td>- ↓↓↓ in HR, ↑↑ in PR interval, ↑ in QTc prolongation with unknown risk of TdP.</td>
</tr>
<tr>
<td>Siponimod</td>
<td>- AAD drugs interactions:</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>- No ECG changes described</td>
</tr>
<tr>
<td></td>
<td>- AAD drug interactions:</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Methyl</td>
<td>- Unknown</td>
</tr>
<tr>
<td>prednisolone</td>
<td>- Unknown</td>
</tr>
<tr>
<td>Interferon</td>
<td>- Unknown</td>
</tr>
<tr>
<td>Alfa-1</td>
<td>- Unknown</td>
</tr>
</tbody>
</table>

Abbreviations: ↑/↓: Mild increase/decrease, ↑↑/↓↓: Moderate increase/decrease, ↑↑↑/↓↓↓: Severe increase/decrease, AAD: Antiarrhythmic drugs, BB: Beta Blockers, CCB: Calcium Channel Blockers, HR: Heart Rate, TdP: Torsades de Pointes
**Arrhythmic manifestations with COVID-19**

- Supraventricular tachycardia
- Atrial Fibrillation
- Atrial Flutter
- Complete Heart Block
- Cardiac Arrest
- Polymorphic Ventricular Tachycardia
- Monomorphic Ventricular Tachycardia
- Multifocal ventricular tachycardia

**Potential mechanisms of arrhythmias**

- Hypoxia
- Myocarditis
- Abnormal host immune response
- Myocardial Ischemia
- Myocardial strain
- Electrolyte derangements
- Intravascular volume imbalances
- Drug side effects

**Management strategies**

- Generalized management: treatment like in all non-COVID critically ill patients
- Specialized management:
  - Consideration in inherited arrhythmia syndrome
  - Management of QTc prolongation in patients receiving COVID-19 therapy
  - Cardiac drug interaction with COVID-19 therapy
- Optimized management:
  - Minimizing exposure to the patients and the EP team
  - Triaging EP procedures
SARS-CoV-2 infection

LUNGS:
- Acute respiratory failure; ARDS

HEART:
- Viral entry into myocardium
- Immune cell-mediated injury

VASCUŁATURE:
- Thrombosis and DIC
- Pulmonary embolism

ABNORMAL HOST IMMUNE RESPONSE:
- Over activation of cardiac sympathetic system
- Immune cell-mediated injury
- IL-6 inhibition of CYP450

GI TRACT:
- Diarrhea

KIDNEYS:
- Acute Renal injury

HYPOXIA
- Anaerobic glycolysis causes altered intracellular pH and gap junction dysfunction
- Depolarization threshold alteration + Temporality
- Reduced electrical coupling + Tissue anisotropy

MYOCARDITIS
- Cytopathic effect and post inflammatory myocardial scarring
- Electrical imbalance
- Re-entry

MYOCARDIAL STRAIN
- Pulmonary hypertension causing increased right sided pressures

MYOCARDIAL ISCHEMIA
- Microvascular dysfunction and pre-existing atherosclerosis
- Elevated heart rate and contractility
- Altered ion hemostasis
- Loss of intercellular connections
- Focal electrical activity and conduction disturbances

MEDICATION EFFECT
- Investigational therapy:
  - (Hydroxy) chloroquine
  - Azithromycin
- Inhibits hERG-K+ channels
- Causes action potential prolongation
- Early after depolarization
- Increased bioavailability of QT-prolonging drugs

INTRAVASCULAR VOLUME IMBALANCE

ELECTROLYTE IMBALANCE

ARRHYTHMIAS
- Tachy or Brady arrhythmias
- QT prolongation
- Torsades de pointes